Publications dans lesquelles il/elle collabore avec Bonaventura Casanova Estruch (12)

2024

  1. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  2. Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

    Neurologia, Vol. 39, Núm. 5, pp. 383-391

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

2017

  1. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

2016

  1. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3

2015

  1. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  2. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  3. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

2014

  1. Biomarkers in multiple sclerosis: An update for 2014

    Revista de Neurologia, Vol. 58, Núm. 12, pp. 553-570

2011

  1. HLA-DRB1 typing in caucasians patients with neuromyelitis optica

    Revista de Neurologia, Vol. 53, Núm. 3, pp. 146-152

  2. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice

    Journal of Immunological Methods, Vol. 371, Núm. 1-2, pp. 170-173

2009

  1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

    Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228